Reports

Drug name	NICE TAs	Comments
Dapagliflozin (Forxiga®)	TA902 - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Dapagliflozin#Amber	TA679 - Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Dapagliflozin#Red	TA597 - Dapagliflozin with insulin for treating type 1 diabetes	Specialist centres only for treating Type 1 diabetes
Daratumumab	TA510 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma TA573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma TA917 - Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable	Hospital use only
Darbepoetin alfa (Aranesp)	TA323 - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy	NHSE commissioned renal dialysis. CCG commissioned for use in cancer - NICE TA323.
Darolutamide (Nubeqa®)	TA660 - Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer TA903 - Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer
Dasatinib tablets	TA425 - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia TA426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia	Hospital use only
Decitabine injection	TA270 - Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)
Degarelix injection	TA404 - Degarelix for treating advanced hormone-dependent prostate cancer	Supported by ESCA
Denosumab injection (Prolia®)	TA204 - Denosumab for the prevention of osteoporotic fractures in postmenopausal women	ESCA

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports